Typical flesh-colored, dome-shaped and pearly lesions
|Classification and external resources|
Molluscum contagiosum (MC) is a viral infection of the skin or occasionally of the mucous membranes, sometimes called water warts. It is caused by a DNA poxvirus called the molluscum contagiosum virus (MCV). MCV has no nonhuman-animal reservoir (infecting primarily humans, though equids can rarely be infected). The virus that causes molluscum contagiosum is spread from person to person by touching the affected skin. The virus may also be spread by touching a surface with the virus on it, such as a towel, clothing, or toys.
Four types of MCV are known, MCV-1 to -4; MCV-1 is the most prevalent and MCV-2 is seen usually in adults. This common viral disease has a higher incidence in children, sexually active adults, and those who are immunodeficient. Molluscum contagiosum is most common in children aged one to 11 years old. MC can affect any area of the skin, but is most common on the trunk of the body, arms, groin, and legs. Some evidence indicates molluscum infections have been on the rise globally since 1966, but these infections are not routinely monitored because they are seldom serious and routinely disappear without treatment. Molluscum contagiosum is contagious until the bumps are gone. Some growths may remain for up to 4 years if not treated.
Signs and symptoms
Molluscum contagiosum lesions are flesh-colored, dome-shaped, and pearly in appearance. They are often 1–5 mm in diameter, with a dimpled center. They are generally not painful, but they may itch or become irritated. Picking or scratching the bumps may lead to further infection or scarring. In about 10% of the cases, eczema develops around the lesions. They may occasionally be complicated by secondary bacterial infections. The viral infection is limited to a localized area on the topmost layer of the epidermis. Once the virus-containing head of the lesion has been destroyed, the infection is gone. The central waxy core contains the virus. In a process called autoinoculation, the virus may spread to neighboring skin areas. Children are particularly susceptible to autoinoculation, and may have widespread clusters of lesions.
Individual molluscum lesions may go away on their own and are reported as lasting generally from 6 weeks, to 3 months. The lesions may propagate via autoinoculation, so an outbreak generally lasts longer. Mean durations for an outbreak are variously reported from 8 to about 18 months, but durations are reported as widely as 6 months to 5 years, lasting longer in immunosuppressed individuals.
Diagnosis is made on the clinical appearance; the virus cannot routinely be cultured. The diagnosis can be confirmed by excisional biopsy.
Histologically, molluscum contagiosum is characterized by molluscum bodies in the epidermis above the stratum basale, which consist of large cells with abundant granular eosinophilic cytoplasm (accumulated virions) and a small peripheral nucleus.
Most studies have found cantharidin to be an effective and safe treatment for removing molluscum contagiosum. This medication is usually well-tolerated though mild side effects are common. Other MC treatment options can cause discomfort to children, so initial recommendations are often expectant management, simply waiting for the lesions to resolve spontaneously.[needs update] Current treatment options are invasive, requiring tissue destruction and attendant discomfort.
Bumps located in the genital area may be treated in an effort to prevent them from spreading. When treatment has resulted in elimination of all bumps, the infection has been effectively cured and will not reappear unless the person is reinfected.
For mild cases, over-the-counter wart medicines, such as salicylic acid may or may not shorten infection duration. Daily topical application of tretinoin cream may also trigger resolution. These treatments require several months for the infection to clear, and are often associated with intense inflammation and possibly discomfort.
Two randomized, double blind, placebo controlled trials have demonstrated the efficacy of a combination of essential oils and iodine in the treatment of molluscum in children.
Imiquimod, a form of immunotherapy, had been proposed as a treatment for molluscum, based on promising results in small case series and clinical trials. However, two large randomized controlled trials, specifically requested by the U.S. Food and Drug Administration under the Best Pharmaceuticals for Children Act and completed in 2006, both demonstrated that imiquimod cream, applied three times per week, after 18 weeks was no more effective than placebo cream in treating molluscum in a total of 702 children aged 2–12 years. In 2007 results from those trials—which have not been published or incorporated into the medical literature—were incorporated into FDA-approved prescribing information for imiquimod, which states: "Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2–12." Imiquimod's FDA-approved prescribing information in 2007 was also updated to document concerning safety issues raised in the two large randomized controlled trials, as well as a smaller pharmacokinetic study (also requested by FDA and subsequently published), including:
- Potential adverse effects of imiquimod use: "Similar to the studies conducted in adults, the most frequently reported adverse reaction from 2 studies in children with molluscum contagiosum was application site reaction. Adverse events which occurred more frequently in Aldara-treated subjects compared with vehicle-treated subjects generally resembled those seen in studies in indications approved for adults and also included otitis media (5% Aldara vs. 3% vehicle) and conjunctivitis (3% Aldara vs. 2% vehicle). Erythema was the most frequently reported local skin reaction. Severe local skin reactions reported by Aldara-treated subjects in the pediatric studies included erythema (28%), edema (8%), scabbing/crusting (5%), flaking/scaling (5%), erosion (2%) and weeping/exudate (2%)."
- Potential systemic absorption of imiquimod, with negative effects on white blood cell counts overall, and specifically neutrophil counts: "Among the 20 subjects with evaluable laboratory assessments, the median WBC count decreased by 1.4*109/L and the median absolute neutrophil count decreased by 1.42×109 L−1."
Surgical treatments include cryosurgery, in which liquid nitrogen is used to freeze and destroy lesions, as well as scraping them off with a curette. Application of liquid nitrogen may cause burning or stinging at the treated site, which may persist for a few minutes after the treatment. Scarring or loss of color can complicate both these treatments. With liquid nitrogen, a blister may form at the treatment site, but it will slough off in two to four weeks. Although its use is banned by the FDA in the United States in its pure, undiluted form, the topical blistering agent cantharidin can be effective.[medical citation needed] Cryosurgery and curette scraping are not painless procedures. They may also leave scars and/or permanent white (depigmented) marks.
Most cases of molluscum will clear up naturally within two years (usually within nine months). So long as the skin growths are present, there is a possibility of transmitting the infection to another person. When the growths are gone, the possibility for spreading the infection is ended.
Unlike herpes viruses, which can remain inactive in the body for months or years before reappearing, molluscum contagiosum does not remain in the body when the growths are gone from the skin and will not reappear on their own. However, there is no permanent immunity to the virus, and it is possible to become infected again upon exposure to an infected person.
One advantage of treatment is to hasten the resolution of the virus. This limits the size of the "pox" scar. If left untreated, molluscum growth can reach sizes as large as a pea or a marble. Spontaneous resolution of large lesions can occur, but will leave a larger, crater-like growth. As many treatment options are available, prognosis for minimal scarring is best if treatment is initiated while lesions are small.
Approximately 122 million people were affected worldwide by molluscum contagiosum as of 2010 (1.8% of the population).
- Acrochordons (also called skin tags—similar in appearance and grow in similar areas)
- Umbilicated lesions
- Wart (caused by the Human papillomavirus; also similar in appearance to molluscum)
- Hanson D, Diven DG (March 2003). "Molluscum contagiosum". Dermatol. Online J. 9 (2): 2. PMID 12639455.
- "Frequently Asked Questions: For Everyone. CDC Molluscum Contagiosum". United States Centers for Disease Control and Prevention. Retrieved 2008-06-29.
- "Molluscum (Molluscum Contagiosum) FAQ". Centers for Disease Control and Prevention. Retrieved 26 December 2013.
- Likness, LP (June 2011). "Common dermatologic infections in athletes and return-to-play guidelines.". The Journal of the American Osteopathic Association 111 (6): 373–379. PMID 21771922.
- "Pamphlets: Molluscum Contagiosum". American Academy of Dermatology. 2006. Retrieved 2008-11-30.
- Weller R, O'Callaghan CJ, MacSween RM, White MI (1999). "Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation". BMJ 319 (7224): 1540. doi:10.1136/bmj.319.7224.1540. PMC 28297. PMID 10591712.
- Molluscum Contagiosum at eMedicine
- MedlinePlus Encyclopedia Molluscum Contagiosum
- Tyring SK (2003). "Molluscum contagiosum: the importance of early diagnosis and treatment". Am. J. Obstet. Gynecol. 189 (3 Suppl): S12–6. doi:10.1067/S0002-9378(03)00793-2. PMID 14532898.
- Torbeck R, Pan M, DeMoll E, Levitt J (June 2014). "Cantharidin: a comprehensive review of the clinical literature". Dermatology online journal (Review) 20 (6). PMID 24945640.
- Prodigy knowledgebase (July 2003). "Molluscum Contagiosum". National Health Service. Retrieved 2010-04-20.—UK NHS guidelines on Molluscum Contagiosum
- "Frequently Asked Questions: For Everyone. CDC Molluscum Contagiosum". United States Centers for Disease Control and Prevention. Retrieved 2008-12-08.
- Schmitt, Jochen; Diepgen, Thomas L. (2008). "Molluscum contagiosum" (PDF). In Berthold Rzany; Williams, Hywel; Bigby, Michael E.; Diepgen, Thomas L.; Herxheimer, Andrew; Luigi Naldi. Evidence-Based Dermatology (PDF). Evidence-based Medicine. London: BMJ Books. ISBN 1-4051-4518-8.
- Credo, BV; Dyment, PG (1996). "Molluscum Contagiosum". Adolesc Med 7 (1): 57–62. PMID 10359957.
- Biomed. & Pharmaco., 58 (2004); 245-247; J. Drugs Dermatol., 11 (2012);349-353
- Hanna D, Hatami A, Powell J, et al. (2006). "A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children". Pediatric dermatology 23 (6): 574–9. doi:10.1111/j.1525-1470.2006.00313.x. PMID 17156002.
- Best Pharmaceuticals for Children Act, Public Law 107-109, January 4, 2002. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm
- DailyMed. Aldara (imiquimod) Cream for Topical use (Prescribing information): http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fccca4e-fb8f-42b8-9555-8f78a5804ed3
- FDA. Label for Imiquimod (Aldara) from 03/22/2007 Efficacy Supplement with Clinical Data to Support. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020723s020lbl.pdf
- Katz, KA; Swetman, GL (2013). "Imiquimod, molluscum, and the need for a better "best pharmaceuticals for children" act". Pediatrics 132 (1): 1–3. doi:10.1542/peds.2013-0116. PMID 23796740. Supplemental information.
- Myhre, PE; Levy, ML; Eichenfield, LF; Kolb, VB; Fielder, SL; Meng, TC (2008). "Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children". Pediatric dermatology 25 (1): 88–95. doi:10.1111/j.1525-1470.2007.00590.x. PMID 18304162.
- Scheinfeld N (March 2003). "Cimetidine: a review of the recent developments and reports in cutaneous medicine". Dermatol. Online J. 9 (2): 4. PMID 12639457.
- Gold, MH; Moiin, A (January 2007). "Treatment of verrucae vulgaris and molluscum contagiosum with photodynamic therapy". Dermatologic clinics 25 (1): 75–80. doi:10.1016/j.det.2006.09.015. PMID 17126744.
- Brown, M; Paulson, C; Henry, SL (Oct 15, 2009). "Treatment for anogenital molluscum contagiosum". American family physician 80 (8): 864. PMID 19835348.
- Vos, Theo; Flaxman, Abraham D; Naghavi, Mohsen; Lozano, Rafael; Michaud, Catherine; Ezzati, Majid; Shibuya, Kenji; Salomonn, Joshua A; Abdalla, Safa; Aboyans, Victor; Abraham, Jerry; Ackerman, Ilana; Aggarwal, Rakesh; Ahn, Stephanie Y; Ali, Mohammed K; AlMazroa, Mohammad A; Alvarado, Miriam; Anderson, H Ross; Anderson, Laurie M; Andrews, Kathryn G; Atkinson, Charles; Baddour, Larry M; Bahalim, Adil N; Barker-Collo, Suzanne; Barrero, Lope H; Bartels, David H; Basanez, Maria-Gloria; Baxter, Amanda; Bell, Michelle L; Benjamin, Emelia J (Dec 15, 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
|Wikimedia Commons has media related to Molluscum contagiosum.|
- Molluscum Center for Disease Control
- Virus Pathogen Database and Analysis Resource (ViPR): Poxviridae